Marty
Well-known member
Experimental anticoagulant fails to meet key treatment goal in late-stage study.
The AP (7/9) reports that ARYx Therapeutics' "experimental anticoagulant tecarfarin failed to meet a key treatment goal in a late-stage study," according to the drugmaker. The research "involved 612 patients with a range of conditions including a history of blood clots, abnormal heart rhythm, and heart attacks."
Dow Jones Newswires (7/8, Barris) reported that "tecarfarin proved to be as effective as in earlier studies but didn't achieve the desired primary endpoint of besting Coumadin [warfarin], which [ARYx] said had a 'virtually unprecedented performance' in the trial." Participants "given tecarfarin stayed within the target therapeutic range 74 percent of the time, while the figure for Coumadin was 73.2 percent."
Bloomberg News (7/9, Polantz, Lee) reports that ARYx "said it plans to continue talks with bigger drug firms about tecarfarin." Reuters (7/9, Nathan) also covers the story
The AP (7/9) reports that ARYx Therapeutics' "experimental anticoagulant tecarfarin failed to meet a key treatment goal in a late-stage study," according to the drugmaker. The research "involved 612 patients with a range of conditions including a history of blood clots, abnormal heart rhythm, and heart attacks."
Dow Jones Newswires (7/8, Barris) reported that "tecarfarin proved to be as effective as in earlier studies but didn't achieve the desired primary endpoint of besting Coumadin [warfarin], which [ARYx] said had a 'virtually unprecedented performance' in the trial." Participants "given tecarfarin stayed within the target therapeutic range 74 percent of the time, while the figure for Coumadin was 73.2 percent."
Bloomberg News (7/9, Polantz, Lee) reports that ARYx "said it plans to continue talks with bigger drug firms about tecarfarin." Reuters (7/9, Nathan) also covers the story
